Electrical Stimulation Emerges as a Powerful Non-Drug Strategy Against Muscle Aging

Sarcopenia—progressive loss of skeletal muscle mass, strength, and function with aging—has reached global prevalence estimates of 10–27%, with rates as high as 21% in Korean men over 70. Despite decades of research, no pharmacological agent has received regulatory approval, and candidates such as myostatin inhibitors have shown limited efficacy with serious safety concerns including cardiac abnormalities and vascular complications. This creates an urgent clinical gap that electrical stimulation (ES) is increasingly positioned to fill.

This comprehensive review, published in Bioactive Materials in 2026, synthesizes the mechanistic, preclinical, and clinical evidence for ES-based sarcopenia therapy. The authors systematically examine how aging disrupts the coordinated interplay among myofibers, motor neurons, microvasculature, extracellular matrix, and immune cells—leading to selective type II fiber atrophy, neuromuscular junction remodeling, oxidative stress, mitochondrial dysfunction, ECM fibrosis, and impaired satellite cell activity. These hallmarks collectively define the pathological landscape ES must address.

Four conventional clinical ES modalities are analyzed in depth. NMES delivers patterned electrical pulses to evoke involuntary muscle contractions and has shown consistent improvements in muscle strength and cross-sectional area in bedridden and post-surgical patients. FES coordinates stimulation with voluntary movement to restore functional motor patterns. PES uses burst-mode waveforms to reduce fatigue during longer sessions. Microcurrent therapy (MT) operates at sub-sensory intensities (microampere range) and appears to modulate cellular metabolism and reduce oxidative stress without frank muscle contraction. Each modality activates distinct intracellular pathways—including mTOR/Akt/S6K for protein synthesis, suppression of FoxO1-driven atrogenes (MuRF1, Atrogin-1), AMPK-mediated mitochondrial biogenesis, and IGF-1/ERK1/2 signaling—supporting muscle preservation at the molecular level.

The review's most forward-looking contribution is its detailed treatment of emerging self-powered ES systems. Triboelectric nanogenerators (TENGs) and piezoelectric nanogenerators (PENGs) harvest mechanical energy from body motion—breathing, walking, or limb movement—and convert it into therapeutic electrical pulses without external batteries. Wearable e-skin patches and implantable nano-electrode systems offer conformal, personalized stimulation with real-time feedback. These platforms have demonstrated efficacy in preclinical muscle atrophy models, promoting hypertrophy, angiogenesis, and anti-inflammatory signaling. The authors argue that regulatory pathways for ES devices are generally more accessible than for drugs, and that materials science advances are rapidly reducing device cost and complexity.

The review acknowledges important limitations. Optimal stimulation parameters (frequency, pulse width, intensity, duty cycle) remain poorly standardized across studies, complicating direct comparisons. Most clinical trials are small, short-duration, and lack active comparators. Long-term safety and efficacy data for implantable nano-systems are absent. Translation from rodent atrophy models to human sarcopenia also remains incompletely validated. Nevertheless, the authors conclude that integrating ES with personalized wearable technology and regenerative medicine represents the most promising near-term path toward precision sarcopenia care.